Metric Finance
LearnFAQ
LearnFAQ

Learn / CDRE

NYSE: CDRE

Cadre Holdings (CDRE) stock, explained like you're 5

Cadre Holdings trades on the New York Stock Exchange under the ticker CDRE. It is a small cap company in the industrial specialties industry, part of the healthcare sector, with a market value of about 1.1 billion dollars.

Ticker
CDRE
Exchange
New York Stock Exchange
Sector
Healthcare
Industry
Industrial Specialties
Size
Small cap, about 1.1 billion dollars

Is Cadre Holdings a small, medium or large cap company?

No. Cadre Holdings is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.1 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Cadre Holdings makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves CDRE stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Cadre Holdings (CDRE) Stock May Be 47% Undervalued On Cash Flow (Yahoo Finance)
  • Our Cadre Holdings Stock Pick Hasn’t Worked Out. We’re Walking Away. (Barron's)
  • Cadre Holdings: A Risky M&A Strategy Worth Betting On (Seeking Alpha)
  • Is It Too Late to Buy Cadre Holdings Inc (CDRE) After 5.2% Rally? GF Value Says Undervalued (GuruFocus)
  • Cadre Holdings stock hits 52 week low at $24.40 (Investing.com)

Follow CDRE in your daily brief

Each trading day at 5 PM ET we post what happened to Cadre Holdings and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow CDRE

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Cadre Holdings stock

What does Cadre Holdings do?

Cadre Holdings trades on the New York Stock Exchange under the ticker CDRE. It is a small cap company in the industrial specialties industry, part of the healthcare sector, with a market value of about 1.1 billion dollars.

What is the ticker symbol for Cadre Holdings?

Cadre Holdings trades under the ticker CDRE on the New York Stock Exchange.

What is Cadre Holdings's market cap?

Cadre Holdings is a small cap stock with a market cap of about 1.1 billion dollars.

How does Cadre Holdings make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves CDRE stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow CDRE stock every day?

Add CDRE to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow CDRE daily

A free brief on Cadre Holdings and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • STE · STERIS plc
  • ZBH · Zimmer Biomet Holdings
  • MAS · Masco Corp /De/
  • AIT · Applied Industrial Technologies

Similar stocks

  • STESTERIS plc
  • ZBHZimmer Biomet Holdings
  • MASMasco Corp /De/
  • AITApplied Industrial Technologies

Compare CDRE: CDRE vs STE, CDRE vs ZBH, CDRE vs MAS

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed